Corvus Pharmaceuticals CRVS Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's accounts receivable?
- Corvus Pharmaceuticals (CRVS) reported accounts receivable of $43K in Q1 2026.
- How has Corvus Pharmaceuticals's accounts receivable changed year-over-year?
- Corvus Pharmaceuticals's accounts receivable decreased by 45.6% year-over-year, from $79K to $43K.
- What is the long-term trend for Corvus Pharmaceuticals's accounts receivable?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's accounts receivable has grown at a -48.0% compound annual growth rate (CAGR), from $507K to $37K.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.